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ABSTRACT: Mitochondrial DNA (mtDNA) mutations
cause a wide range of serious diseases with high
transmission risk and maternal inheritance. Tissue
heterogeneity of the heteroplasmy rate (‘‘mutant load’’)
accounts for the wide phenotypic spectrum observed in
carriers. Owing to the absence of therapy, couples at risk
to transmit such disorders commonly ask for prenatal
(PND) or preimplantation diagnosis (PGD). The lack of
data regarding heteroplasmy distribution throughout
intrauterine development, however, hampers the imple-
mentation of such procedures. We tracked the segrega-
tion of the m.3243A4G mutation (MT-TL1 gene)
responsible for the MELAS syndrome in the developing
embryo/fetus, using tissues and cells from eight carrier
females, their 38 embryos and 12 fetuses. Mutant
mtDNA segregation was found to be governed by random
genetic drift, during oogenesis and somatic tissue
development. The size of the bottleneck operating for
m.3243A4G during oogenesis was shown to be indivi-
dual-dependent. Comparison with data we achieved for
the m.8993T4G mutation (MT-ATP6 gene), responsi-
ble for the NARP/Leigh syndrome, indicates that these
mutations differentially influence mtDNA segregation
during oogenesis, while their impact is similar in
developing somatic tissues. These data have major
consequences for PND and PGD procedures in mtDNA
inherited disorders.
Hum Mutat 32:116–125, 2011. & 2010 Wiley-Liss, Inc.
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Introduction
Mitochondrial DNA (mtDNA, GenBank NC_001807.4) disor-
ders are common diseases with maternal inheritance. Their high
clinical variability is explained, at least in part, by variation of the
mutant load (heteroplasmy) among individuals, and also across
organs and tissues within an individual, so that mutant loads will
surpass the tissue specific threshold, leading to the manifestation of
symptom [Chinnery et al., 1997; Jeppesen et al., 2006]. The usual
severity of these diseases, the recurrence risk, usually high though
being difficult to predict at the individual level, in offspring from
heteroplasmic carriers [Chinnery et al., 1998], and the absence of
efficient therapy, commonly result in a request from at-risk couples
for prenatal (PND) or preimplantation diagnosis (PGD). Such
procedures are, however, hampered by the lack of data regarding
mtDNA segregation during embryofetal development.
In this respect, most available data come from animal studies.
Dramatic shifts of mtDNA populations (variant/wild-type
mtDNA ratio) between the mother and her offspring in cattle
have suggested that a tight bottleneck might account for such a
rapid segregation [Laipis et al., 1988]. One important function of
this bottleneck could be to ensure that new mutations will either
be lost or fixed rapidly within individuals, and thus exposed to
selection at the population level [Bergstrom and Pritchard, 1998;
Roze et al., 2005]. Studies in mice have identified the bottleneck
during oogenesis [Jenuth et al., 1996], through either a reduction
of mtDNA content in primordial germ cells (PGC) [Cree et al.,
2008], or selection of a small effective number of segregation units
for mtDNA [Cao et al., 2007, 2009; Wai et al., 2008]. However,
there are no available data so far regarding mutant mtDNA
segregation in somatic tissues during embryofetal development in
animal models.
In humans, a small number of studies of primary oocytes
carrying mtDNA deletions [Marchington et al., 1998] or point
mutations [Blok et al., 1997; Brown et al., 2001; Marchington
et al., 2010] have suggested that a bottleneck operates during
oogenesis. Random genetic drift appeared as the principal
mechanism determining the level of mutant mtDNA within
primary oocytes from a carrier of the most common mtDNA
mutation, m.3243A4G [Brown et al., 2001]. This mutation
affects the MT-TL1 gene (mitochondrially encoded tRNA leucine
1 [UUA/G]; MIM] 590050), and is responsible for the MELAS
(mitochondrial myopathy, encephalopathy, lactic acidosis, and
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yBoth authors equally contributed to this work.stroke-like episodes; MIM] 540000) [Goto et al., 1992] and
diabetes-deafness syndromes (MIM] 520000) [Manouvrier et al.,
1995; van den Ouweland et al., 1992].
It is so far not known whether m.3243A4G segregation is
governed by random drift in somatic tissues during human
embryofetogenesis. The few available studies on m.3243A4G
carrier fetuses reported a uniform distribution of mutation load
among different tissues from two heteroplasmic 24- and 25-week-
old human fetuses [Cardaioli et al., 2000; Matthews et al., 1994].
Our group found similar mutant loads in chorionic villi and
amniocytes from three heteroplasmic fetuses [Bouchet et al.,
2006]. All these data suggest that MELAS mutant molecules do
not segregate much between 10 to 25 weeks of gestation.
However, we have so far lacked data on the transmission of
m.3243A4G by a carrier to early embryos, and subsequently no
information on segregation of this mutation throughout the entire
period of human embryofetal development has existed. Thanks to
our PGD and PND programs, we collected various tissues and
cells at various stages of development in embryos and fetuses from
m.3243A4G carriers, and investigated local and temporal
variation of the mutant load, using a quantification test designed
to assess m.3243A4G mutant load at the single-cell level.
Aggregation of our data in early embryos and fetuses, with
those from a primary oocyte study in a m.3243A4G carrier
[Brown et al., 2001] indicates that mtDNA segregation is governed
by random genetic drift, in germ and somatic cell lines,
throughout the entire period of human intrauterine development.
The size of the bottleneck operating during oogenesis for
m.3243A4G is additionally suggested to vary between indivi-
duals. Finally, comparison of the current data with those we
previously reported for another common mtDNA mutation,
m.8993T4G( MT-ATP6, ATP synthase subunit 6 gene; MIM]
516060) responsible for the NARP syndrome (Neuropathy, Ataxia,
Retinitis Pigmentosa; MIM] 551500) [Steffann et al., 2006, 2007]
indicates that these two mutations differentially influence mtDNA
segregation during oogenesis, while their putative impact on
mtDNA segregation appears quite similar in somatic cells during
embryofetal development.
Patients, Materials and Methods
Patients
This study was approved by the National Ethics Comittee from
l’Agence de Biomedecine, and all couples gave informed consent
for DNA analyses in themselves and their embryos/fetuses.
PND and/or PGD analyses were carried out in eight individuals
from seven unrelated families, heteroplasmic for the MELAS
m.3243A4G mutation. The questionable predictive value of a
fetal mutant load for the postnatal outcome was emphasized to all
of the couples. In such situations, counseling necessarily refered to
postnatal data, attempting to correlate clinical outcome and
mutant load [Chinnery et al., 1997; Uusimaa et al., 2007;
Whittaker et al., 2009], and to our personal experience with
PGD/PND for another mtDNA disorder, that is, NARP [Gigarel
et al., 2005; Steffann et al., 2006, 2007] and with PND for MELAS
[Bouchet et al., 2006]. Accordingly, we postulated that mutant
loads over 60% during prenatal life might be predictive of a
serious disorder, whereas a mutant load below 30% might
hopefully be associated with absence or low severity of the
disease. The most complex situation was a fetal heteroplasmy
value in the intermediate range (30–60%), a common finding for
the MELAS m.3243A4G mutation in the postnatal period. There
is indeed no available data correlating intermediate mutant load in
the prenatal period with the postnatal outcome.
Seven of the eight couples (couples 2 to 8) elected to resort to a
conventional PND approach at first. Couple 1 declined the option
of pregnancy termination (TOP), and thus directly went to PGD,
that was also offered to couple 2, who had previously experienced
2 TOP after PND. Both couples were informed that, at this early
embryonic stage (day 3), a number of issues remained unsolved,
precluding any conclusive prediction on the pre/postnatal out-
come of a carrier embryo. These couples were offered a PND at 14
gestation weeks (GW) to confirm the PGD result in case of
pregnancy.
Materials
Postnatal period
Mutant loads from carrier females were assessed from blood,
and when available, urine and oral mucosa samples. Single
lymphocytes were isolated from patients 1, 2, 3, 5, and 14 as
already described [Gigarel et al., 2005].
Early embryos
Patients 1 and 2 were subjected to one and three separate PGD
cycles, respectively. A standard in vitro fertilization protocol was
performed and oocytes were collected and fertilized by intracy-
toplasmic sperm injection (ICSI).
A total of 38 embryos were analyzed. Twenty-three of these
embryos were of appropriate quality, and were therefore
submitted to a two-blastomere biopsy at post-ICSI day 3 for
mutant load assessment, as previously described [Gigarel et al.,
2004]. Briefly, under control by a binocular microscope, the
blastomeres were rinsed twice in a drop of PBS supplemented with
0.1% polyvinyl alcohol (Sigma-Aldrich, France), using a mouth-
controlled, finely pulled glass pipette before being transferred into
a transparent microcentrifuge tube containing 3ml of lysis buffer
[Cui et al., 1989]. A small volume of biopsy medium was used as a
PCR negative control for each embryo in order to detect any
contamination by exogenous DNA. In the 15 remaining embryos,
assessment of the mutant load was performed on the embryo in
toto. All blastomeres were separately analyzed, when possible
(couple 1: embryos 1–3, and couple 2: embryo 13). Embryo 10
from couple 2 was cultured up to the blastocyst stage (day 5),
enabling a trophectoderm biopsy as described elsewhere
[McArthur et al., 2005]. The trophectoderm and inner cell mass
were analyzed separately.
Late embryos and fetuses
Prenatal diagnosis was performed in 12 fetuses from 7 carrier
women. Fetus 2c resulted from embryo 7 and 11 transfer after
PGD (patient 2), whereas the remaining ones were conceived
naturally. Chorionic villi (CV, n58), amniotic fluids 1 (AF1,
n56), and 2 (AF2, n51), were sampled at 10, 14, and 30 weeks
of gestation (GW), respectively. Individual fetal cells were isolated
from CV and AF samples from six fetuses, as already described
[Steffann et al., 2007], and analyzed separately, to investigate the
intercellular variation of heteroplasmy. Cord blood was collected
from three fetuses at birth (fetuses 2c, 3, and 4). Postmortem
analyses of various tissues were carried out in two 12-week-old
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TOP, and in a 20-week-old miscarriage product (fetus 7a).
Parental informed consent was obtained for these postmortem
analyses. Fetal tissues were carefully dissected, and small tissue
biopsies were analyzed separately. Multiple samples were taken
from two term placentas (fetuses 2c and 3), and two 12GW
placentas (fetuses 2a and b).
Methods
DNA extraction
DNA was extracted from blood and tissues, using the Nucleon
Bacc3 kit (Amersham Biosciences, UK), and a classical phenol
extraction method, respectively.
Quantitative analysis of the m.3243A4G mutant load
MELAS mutant load was quantified using a semiquantitative
fluorescent PCR-HaeIII restriction test.
Because PCR products analysis using a restriction enzyme is
thought to allow the possibility of errors in mutant load
assessments, secondary to heteroduplex formation during the
PCR process [Tanno et al., 1991], we first validated our method of
heteroplasmy assessment using mixing experiments and standard
curve analysis. Wild-type and mutant plasmids were mixed to
generate 10 samples, each of them comprising 10
6 mtDNA copies,
with the m.3243G4A (mutant) target at concentrations ranging
from 1 to 100%, which were also used to determine the lowest rate
of mutation detection. Each sample was amplified in triplicate,
using both ‘‘single-cell’’ and ‘‘tissue’’ methods, and PCR products
were submitted to HaeIII digestion.
We furthermore ascertained the reliability of our test over a
wide range of mtDNA copies, from 10
2 to 10
6, encompassing the
mtDNA copy number usually present in isolated cells such as
lymphocytes, blastomeres, and oocytes.
Single cells and embryos were transferred to 3ml alkaline buffer
[Cui et al., 1989] and lysed by 10-min heating at 651C. PCR
amplification was carried out using the forward primer (50-
TGAGTTCAGACCGGAGTAATC-30) and the reverse fluorescent
primer ()( 5 0-(6-Fam) CTTAACAACATACCCATGGC-30). Sepa-
rate experimental conditions were devised for whole tissue sample
and single-cell/early embryo analyses.
Tissue sample DNA (1ng) was amplified in a 30-ml reaction
volume containing 1.5U Expand Taq DNA Polymerase, 10  PCR
buffer 2 (3ml; Roche Diagnostics, Mannheim, Germany), 0.5mM
of each primer (Proligo, Paris, France), and 2mM dNTP mix
(Roche Diagnostics, Germany). Initial denaturation was carried
out at 971C for 7min 20sec followed by 20 cycles (971C for 20sec,
601C for 30sec, 681C for 1min 15sec), and final extension of
7min at 681C.
For a single-cell or embryo analysis, the PCR reaction contained
3ml of lysis buffer (lysed cell or negative control), each primer at
0.5mM, master mix 2  (12.5ml, Qiagen Multiplex PCR kit,
Qiagen S.A, Courtaboeuf, France), and double-distilled water up
to a 25-ml final volume. PCR programs were 15min of
denaturation at 951C, followed by 25, 26, 27, and 30 PCR cycles
for whole embryos, trophoblastic cells, blastomeres, and amnio-
cytes, respectively, consisting of 30sec at 941C, 90sec at 601C and
60sec at 721C, with a 30-min final extension at 601C.
The resulting 251-bp fluorescent PCR products (1ml) were
digested for 3hr using 10units of HaeIII and subsequently
submitted to electrophoresis using an automated genetic analyser
ABI3130 (Applied Biosystems, Norwalk, CT). Digestion generated
73-bp and 170-bp fluorescent fragments for the mutant and wild-
type species, respectively. Results were analysed with the Genescan
and Genotyper software (Applied Biosystems). The mutant load
was calculated by dividing the mutant peak area (73bp) by the
sum of normal (171bp) and mutant (73bp) peak areas. Cross-
hybridization of oligonucleotide primers to nuclear DNA was
ruled out by PCR amplification on mtDNA-less Rho0 cells [Parfait
et al., 1998].
Ascertainment of the fetal origin of the CV/AF cells
The fetal origin of single cells collected from CV, AF1, and AF2,
was ascertained by simultaneous analysis of parental and
embryofetal DNA using nuclear (CA)n microsatellite markers
(D6S436, D19S559, D19S559, D16S3395, D6S436, and DXS1073
for fetus 2a, 5a, 5b, 6, 8, and 12b, respectively), enabling to check
for biparental contribution to the cell genotype, and the absence
of fetal cell contamination by maternal DNA [Gigarel et al., 2004].
Amplification of microsatellite markers in single cells required
nested PCR. The first ‘‘outer’’ PCR enabled simultaneous
amplification of the MELAS mutation and an appropriate
microsatellite marker. Briefly, cells were amplified using ‘‘single-
cell’’ PCR conditions described above, as a duplex PCR reaction,
using 0.5mM of each primer. 3ml of the first amplification product
were subsequently mixed with 22ml of ‘‘inner’’ amplification mix,
which contained inner fluorescent microsatellite primers at
0.5mM, master mix 2  (12.5ml, Qiagen Multiplex PCR kit),
and double-distilled water up to a 25-ml final volume. PCR
program was as described above (20 PCR cycles).
Statistical Analyses
Variance analysis and calculation of inter or intra class
correlation coefficients were used to analyze quantitative traits.
Qualitative traits were analyzed using a chi-square test. The 95%
confidence intervals of the measurements from patient 2 were
made by fitting a Kimura distribution [Wonnapinij et al., 2008] to
the 35 mutation level measurements from this patient, and then
drawing 10,000 simulated sets of 35 measurements from this
Kimura distribution to estimate the confidence intervals due to
sample size effects [Wonnapinij et al., 2010].
Results
Sensitivity, Linearity, and Reproducibility of Mutant Load
Quantification
Mixing various proportions of wild-type and mutant plasmids
enabled us to establish that the measured level of heteroplasmy
was a linear function of the expected ratio (Fig. 1). The correlation
coefficient for the observed versus expected proportion of mutant
was 0.99 for both ‘‘single-cell’’ and ‘‘tissue’’ conditions. Triplicate
experiments yielded to similar results (SDo1.7%), and mutant
molecules could be detected in a proportion as low as 2% of the
total mtDNA amount, thus validating reproducibility and
sensitivity of the assay. These results were got with a 10
6 mtDNA
copy number.
To demonstrate an insensitivity to template input amounts for
this particular method, we ascertained the reliability of our test
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2 to 10
6. Results are
displayed in Supp. Figure S1.
Analysis in Carrier Women
Mutant loads from the eight carriers applying for MELAS PND/
PGD (family 1 to 8; Table 1) ranged from 5 to 40%, 8 to 50%, and
15 to 80%, in leucocytes, oral mucosa cells, and urinary tract cells,
respectively. The lowest and highest values were consistently found
in white blood cells (WBCs) and urinary tract cells, respectively, as
expected from previous reports [Chinnery et al., 1997, 1999;
Frederiksen et al., 2006; Whittaker et al., 2009].
Mutant load assessment in single lymphocytes from five carriers
showed large intercellular variations, ranging from 0 to 81%, 0 to
81%, 0 to 95%, 0 to 21%, and 0 to 100% in patients 1, 2, 3, 5, and
14, respectively. When pooling values from all cells analyzed for a
given individual, average mutant load was very close to that
achieved from the overall lymphocyte extract recovered from a
10-ml blood sample.
Comparison of the mean heteroplasmy rate vs one standard
deviation of the heteroplasmy distribution at the single-cell level
for each of the five lymphocyte pools (16.278.6%) showed a 0.92
correlation coefficient (Po0.05) with a positive slope (1.1470.3)
(Table 2 and Supp. Fig. S2).
Analysis in Day 3 to Day 5 Embryos
Thirty-eight embryos from two unrelated heteroplasmic women
were analyzed. The m.3243A4G mutant load was assessed in 31
whole embryos and 70 single blastomeres (Table 3). Exogenous
DNA contamination of the embryonic sample was never detected
in any experiment.
Within the whole cohort of analyzed embryos, six had no
detectable mutation (detection threshold: 2%). Taking into
account Patient 2 only (35 embryos), the transmission rate was
83%. None of the embryos were homoplasmic mutant. Hetero-
plasmy levels ranged from 5 to 77%, with an apparently
homogeneous dispersion of the mutant rates among embryos.
The mutant load value was similar in all blastomeres derived from
a single embryo (n52–11) with a 6% maximal interblastomere
variability. The intraclass correlation coefficient (ICC) was equal
to 0.994, consistent with the high level of agreement of
intraembryo measurements, and contrasting with the interembryo
variability. When possible, comparison of heteroplasmy levels
between the whole embryo (collected at day 5) and two of his/her
blastomeres (collected at day 3) showed a variation rate o7% in
13/16 embryos, and between 10 and 15% in the remaining ones.
When considering all embryos from patient 2, the distribution
of the mutation level values was consistent with the distribution
predicted from neutral drift theory (P-value of 0.53 by KS test)
comparing the data against the null hypothesis of the Kimura
distribution [Wonnapinij et al., 2008]. When pooling mutant
loads measured in each embryo from a given woman, mean values
were 30715% and 32723% for patients 1 and 2, respectively.
Each of these values was close to the mutant load measured in oral
mucosa cell DNA from the corresponding woman (30 and 27%
for patients 1 and 2, respectively).
Embryo 10 from family 2, harboring a 13% mutant load at day
3, was cultured up to the blastocyst stage (day 5) and separated in
2 parts, namely, the inner cell mass and the trophectoderm. PCR
failed to amplify the inner cell mass DNA, while the heteroplasmy
level of the trophectoderm was consistent with the level measured
in day 3 blastomeres (15 vs. 13%).
Analysis in Fetuses over 10GW
Mutant loads were assessed in extraembryonic or embryonic
tissues collected between 10 GW to term, in 12 fetuses from 7
carriers (families 2 to 8; Table 4).
One fetus did not carry the mutation in his two tested tissues
(amniocytes at 16GW, and cord blood at birth, fetus 4). As observed
in early embryos, no fetus was homoplasmic for the mutant. The
mutation load ranged from 4 to 79% in the 11 carriers. There was
no substantial variation in mutant loads assessed at various stages of
pregnancies until birth (Table 4). When excluding data from extra-
embryonic tissues (10GW trophoblast or at term placenta),
m.3243A4G mutant loads were identical in all tested tissues from
ag i v e nf e t u s( m e a n 7SD: 74.670.7% [three tissues], 4270.8%
Figure 1. Standardization of m.3243A4G load assessment. The
rate of m.3243A4G heteroplasmy was assessed by semiquantitative
fluorescent PCR using 10 samples containing various proportions of
mutant plasmid. Each sample comprised 10
6 mtDNA copies. Each
value is the mean of three independent experiments. Bars depict
standard deviations. WT: wild-type DNA.
Table 1. Maternal m.3243A4G Mutant Load
Mutant load (%)
Patient WBC OMC UTC
A 12 03 0 6 5
22 02 7 3 0
32 04 0 5 0
478 1 5
5 5 10 35
63 05 0 8 0
73 0 7 0
84 0 5 5
B 93 94 8
10 20
11 63
12 34 45 80
13 21
A, Patients analyzed in this study. B, Patients reported elsewhere: [9] Matthews et al.,
1994, [10] Cardaioli et al., 2000, [11] Chou et al., 2004, [12,13] our group [Bouchet
et al., 2006]. WBC, white blood cells; OMC, oral mucosa cells; UTC, urinary tract
cells.
HUMAN MUTATION, Vol. 32, No. 1, 116–125, 2011 119[five tissues], 7172% [five tissues], and 7870.9% [seven tissues]
for fetuses 2a, 2b, 5b and 7a, respectively). When placenta and other
tissues were available at the same term of gestation (three fetuses),
values were similar in two fetuses (74.6 vs. 74% and 78 vs. 78% for
fetus 2a and 7a, respectively), while fetus’ 2b mutant load was higher
in placenta than in other tissues (5772% vs. 4272%, respectively).
Multiple samples in various parts of placenta, aimed at testing the
mutant load distribution, did not show any substantial variation in
2, 6, 10, and 18 various loci of fetuses’ 2a, 2b, 2c, and 3 placentas,
respectively (Table 4), irrespective of the gestation stage (12GWor at
birth).
Single trophoblastic cells (n583) and amniocytes (n564)
were isolated from six fetuses to investigate the intercellular
mutant load variation (Fig. 2). Simultaneous analyses of parents’
and fetal cell DNAs using a polymorphic marker proved the fetal
origin and the absence of contamination by maternal DNA of the
analyzed cells (not shown). Large intercellular variations were
found both in trophoblastic cells (range: 7–21%, 6–38%, 23–55%,
23–70%, and 64–100%, for fetuses 5a, 6, 12b, 8, and 2a,
respectively), and amniocytes, either at 14GW (range: 10–23%,
16–42%, and 52–94%, for fetuses 12b, 6 and 5b, respectively), or
at 30GW (range: 9–17% and 5–28% in fetuses 5a and 12b,
respectively). When pooling values from all cells analyzed for a
given cell type in a given fetus, the average mutant loads were very
close to those achieved from overall chorionic villi sampling
(CVS) and amniotic fluid sample (AFS) mutant loads (variation
o10%; Fig. 2).
Comparison of the mean heteroplasmy rate versus one standard
deviation of the heteroplasmy distribution at the single-cell level
for each of the 10 fetal cell pools (34.3723%) showed a 0.81
correlation coefficient (Po0.01) with a positive slope (0.1370.03)
(Table 2 and Supp. Fig. S2).
Predictive Value of a Prenatal Mutant Load for the
Postnatal Outcome
Assessment of the predictive value of a prenatal mutant load for
the disease severity in the postnatal period is of crucial
importance. A follow-up of our small cohort of patients born
after PGD (n51) or PND (n59) provided a preliminary
indication, even though for ethical reasons we could not check for
the presence of the mutation in these asymptomatic children. All
these children, harboring mutant loads between 0 and 35% in
prenatal period, are indeed healthy at 1 month to 5 years of age
(Table 4).
Discussion
Analysis of tissues and cells from human embryos and fetuses is
currently the only approach to get some insight into processes that
govern maternofetal transmission of common mtDNA mutations
in humans, owing to the numerous technological difficulties met
in attempts at creating animal models of mitochondrial disorders
[Fan et al., 2008; Inoue et al., 2000]. We used this approach to
study the segregation of m.3243A4G mtDNA molecules during
human in utero development, thanks to our PND/PGD activities,
offered to carriers of this mutation.
Table 2. m.3243A4G Mutant Load in Single Cells of Various Origins
Lymphocytes Syncitiotrophoblasts/amniocytes Muscle fibers
a
Number of patients 5 5 8
Number of cell pools 5 10 21
Total cell number 84 147 341
Heteroplasmy level (mean7SD) 16.278% 34.3713% 78.5717%
Correlation coefficient (p) 0.92 (o0.05) 0.81 (o0.05) 0.84 (o0.01)
Slope7SD 1.1470.28 0.1370.03  0.3870.05
aCalculation from data by Tokunaga et al. [1994]; Petruzzella et al. [1994]; Silvestri et al. [2000].
Table 3. m.3243A4G Mutant Load in Preimplantation Embryos
Single blastomere
Overall Mean
Patient Embryo Blastomere 1 Blastomere 2 embryo Median (7SD)
11 1 8 71( n56)
22 3 72( n55) 23% 30715%
35 0 73( n53)
210
a 0
20 0
30 0 0
40
50
60
75 5
87 8
91 2 1 4
10 13 13 I
b T: 15
11 13 16
12 17 22 15
13 14 15 1672( n511)
14
b 25 23
15 27 27 23
16 28
17 15 21 30
18 40 41 37 37% 32723%
19 42
20 42
21 43
22 47
23 51 55 48
24 50
25 50
26 39 40 50
27 54 55 50
28 55
29 60
30 55 55 62
31 63 66 63
32 51 54 66
33 67 68 74
34 72 77
35 69 71 75
Patient numbering refers to Table 1. Individual values (1) represent the heteroplasmy
level of two single blastomeres or of embryos in toto, (2) are expressed as mean7SD
when more than two blastomeres from one embryo were analyzed (number of
analyzed blastomeres in parentheses). Embryo 10 from family 2 was separated in two
parts before PCR analysis, that is, the inner cell mass (I), and the trophectoderm (T).
Calculation of ‘‘overall mean value’’ and ‘‘overall median value’’ took into account
either the mean of the values achieved through analysis of all blastomeres when only
blastomeres were available, or values from embryos only in other cases.
aDetection threshold: 2%.
bPCR failure.
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devised for the quantification of the m.3243A4G MELAS
mutation in tissues and single cells.
Although last-cycle labeling PCR indeed is a well-established
and agreed-upon standard protocol for the quantification of
mtDNA heteroplasmy, a major concern with this approach is the
need to add the labeled primer prior to the last PCR cycle. This
process indeed runs a significant risk of contamination of both
the endogenous PCR product by exogenous DNA, and of the
laboratory dedicated to single-cell analyses by the endogenous
PCR product. Such a risk, being a minor one when amplifying a
large amount of DNA, becomes a major hurdle to the use of this
method, when applied to single-cell analysis.
We ascertained the reliability of our test over a wide range of
mtDNA copies, from 10
2 to 10
6. This range encompassed the
mean value of mtDNA copies in lymphocytes (around 150 copies)
[Maagaard et al., 2006; Urata et al., 2008], blastomeres
(11,000–449,000 copies) [Lin et al., 2004], and oocytes
(200,000–800,000 copies) [Craven et al., 2010]. Our results
demonstrated an insensitivity to template input amounts for this
particular method, thus validating the results of the experiments
carried out on various cells and tissues.
Analysis in Day 3 to Day 5 Embryos
To our knowledge, data on the presence of the m.3243A4G
mutation at the day 3 stage of embryonic development have not
been reported so far. This mutation was found in 32 of 38
embryos (84%) from two unrelated carriers. This transmission
rate is in agreement with a previous report on the presence of
m.3243A4G in adult carrier’s primary oocytes [Brown et al.,
2001], whose 74 of 82 oocytes (90%) were heteroplasmic.
A woman carrying the pathogenic mutation may thus have
mutation-free embryos, advocating PGD as an appropriate
procedure for preventing recurrence of affected offspring in
carriers, at least in the mutant load range reported in this study.
Mutant DNA molecules were constantly found to be equally
distributed among the various blastomeres of a carrier embryo until
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Figure 2. Distribution of m.3243A4G mutation levels across isolated
cells. MELAS mutant load was assessed in trophoblastic cells sampled
at 10GW (open boxes) and amniocytes sampled at 14 (hatched boxes)
or 30 (filled boxes) GW in six fetuses (numbering refers to Table 4). n:
number of analyzed cells. Each box depicts the mean mutant load plus
(top bar), and minus 1 standard deviation (bottom bar) for a given cell
pool. Whiskers depict maximal (top) and minimal (bottom) values for
each sample. Central bar: median. Mean mutant load assessed on the
whole chorionic villi, or amniocyte sample.
HUMAN MUTATION, Vol. 32, No. 1, 116–125, 2011 121day 5, in agreement with data on mtDNA polymorphisms achieved in
mouse [Dean et al., 2003] and human embryos [Marchington et al.,
2010], as well as on the m.8993T4G( N A R P )m u t a t i o ni nh u m a n
[Steffann et al., 2006]. Single-cell analysis thus reflects the whole
embryo mutant load, supporting relevance of the usual PGD
procedure for assessment of the overall embryo genotypic status. It
is, however, worth noting some occasional variability (up to 15%) in
mutant load between single-cell measurements and the whole
embryo. This discrepancy could have arisen from either a technical
artifact (such as partial loss of mitochondrion during whole embryo
recovery) or physiological distortion in m.3243A4Gs e g r e g a t i o n
from day 3 (blastomere sampling stage) to day 5 (whole embryo
recovery stage). This last hypothes i si su n l i k e l yb e c a u s em u t a n tl o a d
values were very close in day 5 trophectoderm and day 3 single
blastomeres in the only embryo where both tissues were available
(Table 3), additionally indicating that the mtDNA molecule
segregation is not skewed across embryonic and extraembryonic cells
(trophectoderm) at this developmentals t a g e .F i n a l l y ,i n t e rb l a s t o m e r e
stability of the mutant load suggests that embryonic heteroplasmy
determined from a single-cell analysis provides an accurate estimate of
the whole embryo mutant load, as previously reported for other
mtDNA variants [Craven et al., 2010; Steffann et al., 2006].
The m.3243A4G mutant load was found to be highly
heterogeneous among various embryos from a given individual,
ranging from 18 to 50% and from 0 to 77% in patients’ 1 and 2
embryos, respectively. These values on ‘‘early’’ embryos are in
agreement againwith those on primary oocytes from a m.3243A4G
carrier, the mutant load of which ranged from 1 to 50% [Brown
et al., 2001]. Two conclusions can be derived from these
observations.
The first conclusion concerns the mode of transmission of
m.3243A4G from the mother to her progeny. The distribution of
the mutation level values among patient 2’s embryos was consistent
with the Kimura distribution calculated from the neutral drift theory.
Furthermore, an equal number of her embryos were found to harbor
a mutation level greater than the mean value (18 embryos) and less
than the mean (17 embryos). Finally, the mean level of heteroplasmy
amongst all embryos was very close to the heteroplasmy level seen in
the mother (oral mucosal cells and blood, patients 1 and 2). These
data argue for random genetic drift as the mechanism governing
mtDNA segregation during oogenesis. This observation in humans is
in full agreement with the results of a study of heteroplasmy
distribution in the progeny of mice carrying apparently neutral BALB/
c and NZB mtDNA sequence variants [Jenuth et al., 1996]. Assuming
that blastomere analysis provides a direct insight on mature oocyte
mutant load, our data, gathered with those of Brown et al., suggest
that mtDNA segregation is governed by a random genetic drift
mechanism over the whole oogenesis period.
The second conclusion regards the size of the bottleneck operating
for m.3243A4G during oogenesis (Table 5). The embryos from
patient 2 had a larger normalized variance [Wonnapinij et al., 2010],
and therefore a smaller bottleneck parameter, than the oocytes from
the individual in Brown’s study [Brown et al., 2001]. The confidence
intervals did not quite overlap, indicating that there is a real difference
between the bottleneck sizes in these two individuals, although this
difference is not large. These data therefore suggest that some
individual-dependent parameter modulates the bottleneck size for a
given mtDNA mutation.
Analysis in 10–37GW Fetuses
Very few data are available on m.3243A4G segregation during
fetal development so far. We looked for this mutation in 12 fetuses
from 8 carriers, and aggregated these data with those that we
(patients 12 and 13; Table 4) [Bouchet et al., 2006] and other
groups (patients 9 to 11; Table 4) [Cardaioli et al., 2000; Chou
et al., 2004; Matthews et al., 1994] had previously published.
Maternal m.3243A4G was passed on to 17 of 20 fetuses (85%
transmission rate). Taking embryonic and fetal data together,
carriers passed on the mutation to 49 of their 58 offspring (84%;
Tables 3 and 4). This transmission risk fits with the MELAS
transmission rate calculated from the mutant load determined in
buccal mucosa samples from carriers’ offspring in the postnatal
period [Uusimaa et al., 2007]. It cannot be ascertained whether
the three fetuses shown to be mutation-free at 10GW in the
current study were mutation-free embryos initially or alternatively
resulted from subsequent loss of mutant mtDNA molecules they
carried at early embryonic stage. All fetuses but one (fetus 2c) were
indeed conceived out of a PGD procedure, and mutant load values
at the day 3 stage were therefore not available. Our data however
argue for mutant load stability throughout the entire period of
embryofetal development. In fetus 2c, loads in 14-GWamniocytes
and in term cord blood were indeed 4 and 5%, respectively, in
agreement with those assessed at early embryonic stage (embryos
7 and 11 from patient 2, carrying 5 and 14%, respectively, only
one of whom, fetus 2c, developed). We similarly did not find any
temporal variation of the MELAS mutant load in multiple samples
taken within 10 to 39GW (Table 4A and B).
Study of various tissues from six 12–25GW fetuses (2a, 2b, 5b,
7a, 9, 10) showed a tight intertissue stability in each of them.
Mutant load assessed in extra-embryonic (placenta) and embryo-
nic tissues collected at the same gestation term from four fetuses,
was found to be similar in three of them (2a, 7a, and 9), being
higher in trophoblast (57 vs. 42%) from the remaining one (fetus
2b). Discrepancy between trophoblast and nontrophoblastic fetal
tissues did not seem to result from an ascertainment bias
secondary to locoregional mutant load heterogeneity within
placenta, recently shown to exist [Marchington et al., 2006]. The
heteroplasmy level was indeed highly similar in six separate
regions of fetus 2b placenta (Table 4). Thus, this placento-fetal
discrepancy might be accounted for by selection of a few cells that
will form the first source for the placental membranes in the
partitioning blastocyst. This observation additionally emphasizes
that analysis of single CVS sample, carried out in a PND frame,
may fail to assess the fetal mutant load reliably, as recently
reported [Marchington et al., 2010].
The observation of tight mutant load stability, both across
tissues and with time, in all tested fetuses, suggests that mtDNA
segregation is mainly governed by random genetic drift in somatic
tissues throughout the entire period of human embryofetal
Table 5. Comparative Analysis of Mutation Levels in
Preimplantation Embryos from Patient 2 and Primary Oocytes
from a Published Report
Patient 2 Brown et al., 2001
Sample size (n)3 5 8 2
Mean mutation level (p0) 33.7% (25.8–42.1%) 12.6% (10–15%)
Mutation level variance (V) 0.06 (0.037–0.086) 0.014 (0.009–0.020)
Normalized variance (V/(p0(1 p0))) 0.27 (0.18–0.38) 0.13 (0.09–0.17)
Bottleneck parameter (b) 0.72 (0.62–0.82) 0.87 (0.83–0.91)
Probability of fixing on wild-type 8.4% (1.5–19%) 14% (6–24%)
Probability of fixing on the mutant 0.4% (0–2.0%) 2 10
 7 (0–1 10
 6)
Probability of having 460% mutant 17% (7–27%) 0.3% (0.02–0.8%)
Values are given as mean (95% confidence intervals). The distribution of the
mutation level values from patient 2 was consistent with the Kimura distribution
(P-value of 0.53 by KS test).
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the 20 fetuses analyzed so far (Table 4) was found to carry a
heteroplasmy rate exceeding 80%, over a wide range of maternal
mutant loads (from 5% in WBCs to 80% in urinary tract cells).
Whether such a 80% value has a biological significance (i.e., a
hypothetical selection against highly mutated embryos/fetuses)
remains speculative. Because mutations such as m.3243A4G
exhibit a relatively normal pattern of distribution around the
maternal mean, it would be unlikely, given the relatively small
sample size and the mean maternal mutant load value in majority
below 40% (in blood) in our series (Table 1) to find embryos with
greater than 80% heteroplasmy, even in the absence of selection.
We attempted to establish at the single-cell level the basis of the
mutant load stability observed across fetal tissues. We thus
analyzed 147 cells distributed into 10 pools of trophoblastic or
amniotic cells (7–30 cells per pool) collected in six unrelated
fetuses within the 10–30-GW period (Fig. 2). Except for one
homoplasmic mutant cell (fetus 2a), all cells were heteroplasmic
with a mutant load ranging from 5 to 95%. This observation is in
line with the few studies available on MELAS single cells collected
during the postnatal life, that indeed failed to detect mutant loads
over 92% and 98% in lymphocytes [Saitoh et al., 1999] and
muscle fibers [Silvestri et al., 2000], respectively. These data argue
that, over a critical threshold of heteroplasmy, the resulting impact
on respiratory chain function promotes fetal cell death [Sasarman
et al., 2008].
When pooling values from all cells belonging to a given pool,
mutant load dispersion ranged from 10 to 47% (Fig. 2). The
frequency distribution of a single-cell mutant load within each of
the 10 cell pools corresponded to a binomial distribution, with a
median value identical or very close to the mean value of
heteroplasmy, in keeping with the random genetic drift mechan-
ism. We subsequently looked for an optional relationship between
a mutation rate at the tissue (chorionic villi or amniocytes) level
and the amplitude of mutant load dispersion at the single-cell
level in this tissue (Supp. Fig. S2). A previous study using adult
carrier lymphocytes had indeed suggested that the higher the
proportion of mutated mtDNA molecules, the wider the
dispersion of heteroplasmy level [Saitoh et al., 1999]. Although
the number of single cells analyzed was low in each pool, we
however assumed that each of the 10 cell pools was fairly
representative of the whole tissue sample, based on mean mutant
load variation consistently less than 10% between the cell pool and
the whole sample. It clearly appeared that the higher the tissue
mutant load, the larger the heteroplasmy dispersion in tropho-
blastic and amniotic cells, even if the low number of analyzed cells
precluded any firm conclusion on the biological relevance of this
observation. We then attempted to evaluate whether such a
hypothetical relationship can be considered in various tissues from
m.3243A4G carriers, collected in prenatal and postnatal periods
as well. We considered that Saitoh’s study was exposed to some
bias in heteroplasmy assessment, due to the complex experimental
procedure of this study (first PCR, electrophoresis gel extraction
of the PCR products, second PCR, PCR products enzymatic
digestion, Southern blotting, and bioimager analysis). Using DNA
from five adult carrier females, we therefore recapitulated Saitoh’s
study with our own method of mutant load assessment, in an
effort to homogenize our data. We thus found a statistically
significant correlation between the mean mutant load in each of
the five lymphocyte pools and the heteroplasmy distribution at the
single-cell level. Interestingly, comparison of our data in
lymphocytes and fetal cells showed a marked difference between
curve slopes for a same range of heteroplasmy, arguing for some
tissue-dependence of mtDNA segregation at the cell level (Supp.
Fig. S2). These data contrast with the few available data of the
literature, regarding single muscle fibers in adult carriers. The
latter indeed showed that, the higher the mean mutant load of a
cell pool, the lower the heteroplasmy distribution at the cell level
[Petruzzella et al., 1994; Silvestri et al., 2000; Tokunaga et al.,
1994]. However, the range of mutant loads does not overlap
between skeletal muscle (60–100%) and the other tissues (5–60%).
Thus, assuming that the apparent relationship between mean
mutant loads at a whole sample level and mutant load dispersion
at the single-cell level makes biological sense in all these tissues, it
would remain to be seen whether the proposed tissue dependance
of such correlations is valid throughout the 0–100% range of
heteroplasmy.
Comparison of Prenatal and Postnatal Data
It is difficult to reconcile the prenatal intertissue stability
observed in this study, and the tissue-dependance of m.3243A4G
mutant loads in adult carriers, who harbor heteroplasmy rates
almost constantly higher in skeletal muscle, urinary epithelial tract
cells, and hair follicles, than in white blood cells [Chinnery et al.,
1999; Frederiksen et al., 2006; Whittaker et al., 2009].
This tissue dependance has been suggested to result from a
replicative disadvantage of cells harboring a high mutant load,
thus promoting ‘‘mutation epuration’’ from fast regenerating
tissues. Should such a biological process operate prenatally, it
could be missed out within the ‘‘short’’ course of a pregnancy, by
reference to the very slow decrease of mean mutation level in adult
white blood cells [Rajasimha et al., 2008], thus reflecting the
apparent intertissue mutant load stability throughout the prenatal
period. Alternatively, cell proliferation rate would be identical
among all tissues throughout intrauterine life, and would become
tissue dependent from a fairly late postnatal period. A similar
value of mutant load (65–70%) has indeed been reported in
amniocytes at 21GW, and in peripheral blood and hair follicles
sampled in a 4-year-old carrier [Chou et al., 2004].
Comparison of mtDNA Metabolism in m.3243A4G
(MELAS) and m.8993T4G (NARP) Mutations Throughout
Human Embryofetal Development
Comparing mtDNA segregation data throughout human
embryofetal development for two different mtDNA mutations,
namely, m.3243A4G/MELAS and m.8993T4G/NARP, highlights
striking differences (Fig. 3).
Although all MELAS embryos herein reported, originating from
20%-mutant load carriers, are mutation-free or heteroplasmic up
to 75% with an apparently random distribution of heteroplasmy,
the only two reports on m.8993T4G at day 3 to day 5 embryonic
stage indicated that the three NARP embryos from a 18% mutant
load carrier were either wild-type or mutant homoplasmic
[Steffann et al., 2006]; the five remaining ones carrying low levels
of heteroplasmy (4–22%) [Tajima et al., 2007]. Although the low
number of embryos analyzed so far precludes drawing firm
conclusion on a putative difference of segregation between
m.8993T4G and m.3243A4G molecules during oogenesis, these
apparently different patterns of segregation are, however, sub-
stantiated by the few available analyses of primary oocytes from
carriers of these mutations [Blok et al., 1997; Brown et al., 2001].
A wild-type (1/7) or mutant homoplasmic state (6/7) was indeed
the rule in the seven NARP primary oocytes from a 50% mutant
load carrier, contrasting with the presence of heteroplasmy in 90%
HUMAN MUTATION, Vol. 32, No. 1, 116–125, 2011 123of 82 primary oocytes in a m.3243A4G carrier with a 8% mutant
load in WBC. It can be speculated from these data that bottleneck
would be of different size between m.3243A4G and m.8993T4G.
Whether a purifying selection operates in the human germline
against m.8993T4G and m.3243A4G is a matter of debate. Our
data in early NARP embryos [Steffann et al., 2006], those from the
analysis of primary oocytes in a m8993T4G carrier [Blok et al.,
1997], as well as our previous report on two fetuses with a mutant
load over 85% from two m8993T4G carriers with a 30% mutant
load in WBCs [Steffann et al., 2007], clearly argue against such a
negative selection for this mutation in human. As mentioned
above, no conclusion can be drawn at this point on the occurrence
of a purifying selection against m.3243A4G in the human germ
line, owing to the limited number of data we achieved, all drawn
from low (20%) mutant load carriers. It has, however, to be
emphasized that we never observed any fetus with a mutant load
over 80% among the eight pregnancies from six m.3243A4G
carriers with a WBC mutant load equal or even higher than 30%
(patients 6–9, 11, 12; Table 1). These data are difficult to reconcile
with those from murine germline segregation studies, indicating
that mutations in protein coding genes of mtDNA are strongly
selected against, whereas mutations affecting tRNA genes (such as
m.3243A4G) are largely refractory from such a process [Fan
et al., 2008, Stewart et al., 2008].
Regarding the somatic tissue development, we previously
showed the existence of fetuses carrying m.8993T4G with various
degrees of mutant loads, from 0 to 100%, over the 10-GW stage of
pregnancy until delivery [Steffann et al., 2007]. m.8993T4G and
m.3243A4G mutant loads remain at a steady-state level with time
or across various tissues, thus supporting a random segregation of
mutant mtDNA molecules throughout somatic embryo-fetogen-
esis irrespective of the mutation type.
In conclusion, one can speculate that the bottleneck size, and
possibly, the mutant load threshold critical for embryo/fetus
survival, varies among mtDNA mutations, thus hampering genetic
counselling and PND/PGD procedures in mitochondriopathies
resulting from ‘‘private’’ mtDNA mutations. To test this specula-
tion, we will need to collect data on mtDNA mutant loads for
other rarer mtDNA mutations.
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